Carmat

Carmat SA is a French medical device company based in Vélizy-Villacoublay, specializing in the design and development of a total artificial heart for patients with end-stage biventricular heart failure. Founded in 2008, Carmat aims to provide a durable alternative to heart transplants, addressing a significant public health issue as heart failure is a leading cause of death in the Western world. The company's flagship product, the Aeson® Total Artificial Heart, is an active implantable device that replaces the ventricles of the native heart. It is designed to mimic the heart's natural function and provides mechanical circulatory support. The Aeson® device is powered by an external system, allowing patients to maintain mobility and a near-normal lifestyle. Currently, it is commercially available in Europe and is indicated as a bridge to transplant for patients with advanced heart failure. In the U.S., it is available through clinical trials. Carmat's primary customers include cardiologists, cardiac surgeons, hospitals, and patients requiring mechanical circulatory support. The company is committed to improving the quality of life and survival rates for those with advanced heart failure through innovative technology.

• Employees 170
• Founded 2008
• Annual Revenue $7292000
• Total Funding $55446990